ACCESS BIOTECHNOLOGY
Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – from discovery-stage technology platforms to late-stage clinical programs. The company is based in New York.
ACCESS BIOTECHNOLOGY
Social Links:
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
1986-01-01
Status:
Active
Contact:
(212) 247-6400
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Apache Sitelinks Search Box Yoast WordPress SEO Plugin Yoast SEO Premium Yoast Plugins PHP
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program makes investments in faculty-driven cell therapy, gene therapy, and connected health companies
Current Employees Featured
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-08-10 | Disc Medicine | Access Biotechnology investment in Venture Round - Disc Medicine | N/A |
2022-07-12 | Areteia Therapeutics | Access Biotechnology investment in Series A - Areteia Therapeutics | 350 M USD |
2022-06-02 | Upstream Bio | Access Biotechnology investment in Series A - Upstream Bio | 200 M USD |
2021-12-01 | Curie Therapeutics | Access Biotechnology investment in Series A - Curie Therapeutics | 75 M USD |
2021-11-15 | Recludix Pharma | Access Biotechnology investment in Series A - Recludix Pharma | 60 M USD |
2021-09-02 | Disc Medicine | Access Biotechnology investment in Series B - Disc Medicine | 90 M USD |
2021-07-13 | Nimbus Therapeutics | Access Biotechnology investment in Venture Round - Nimbus Therapeutics | 105 M USD |
2021-05-24 | Eliem Therapeutics | Access Biotechnology investment in Series B - Eliem Therapeutics | 60 M USD |
2021-03-25 | Eliem Therapeutics | Access Biotechnology investment in Series A - Eliem Therapeutics | 80 M USD |
2021-03-01 | DTx Pharma | Access Biotechnology investment in Series B - DTx Pharma | 100 M USD |